VEGFA and myocardial infarction: Maloney et al. [45], however, based on meta-analysis, did not determine that the use of any of the three VEGF inhibitors: aflibercept; brolucizumab; ranibizumab was related to a heightened risk of acute cerebrovascular disease, major bleeding, myocardial infarction, or all-cause hospitalization [45,46].